The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $21.53 in the prior trading day, Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $21.17, down -1.67%. In other words, the price has decreased by -$1.67 from its previous closing price. On the day, 0.86 million shares were traded. NTLA stock price reached its highest trading level at $21.73 during the session, while it also had its lowest trading level at $21.03.
Ratios:
Our goal is to gain a better understanding of NTLA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.67 and its Current Ratio is at 8.67. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 23, 2024, Downgraded its rating to Neutral and sets its target price to $32 from $136 previously.
On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $66.Canaccord Genuity initiated its Buy rating on April 13, 2023, with a $66 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when BASTA JAMES sold 2,297 shares for $32.99 per share. The transaction valued at 75,778 led to the insider holds 81,571 shares of the business.
Clark Eliana sold 605 shares of NTLA for $19,959 on Mar 04 ’24. The EVP, Chief Technical Officer now owns 71,470 shares after completing the transaction at $32.99 per share. On Jan 08 ’24, another insider, Sepp-Lorenzino Laura, who serves as the EVP, Chief Scientific Officer of the company, sold 2,275 shares for $28.87 each. As a result, the insider received 65,682 and left with 43,927 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 2034572544 and an Enterprise Value of 1237695616. For the stock, the TTM Price-to-Sale (P/S) ratio is 56.29 while its Price-to-Book (P/B) ratio in mrq is 1.87. Its current Enterprise Value per Revenue stands at 34.12 whereas that against EBITDA is -2.445.
Stock Price History:
Over the past 52 weeks, NTLA has reached a high of $47.48, while it has fallen to a 52-week low of $20.78. The 50-Day Moving Average of the stock is -21.51%, while the 200-Day Moving Average is calculated to be -31.65%.
Shares Statistics:
The stock has traded on average 1.55M shares per day over the past 3-months and 1181520 shares per day over the last 10 days, according to various share statistics. A total of 96.44M shares are outstanding, with a floating share count of 94.19M. Insiders hold about 2.33% of the company’s shares, while institutions hold 88.42% stake in the company. Shares short for NTLA as of 1711584000 were 14833304 with a Short Ratio of 9.57, compared to 1709164800 on 12616622. Therefore, it implies a Short% of Shares Outstanding of 14833304 and a Short% of Float of 17.29.
Earnings Estimates
The stock of Intellia Therapeutics Inc (NTLA) is currently drawing attention from 22.0 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of -$1.38 for the current quarter, with a high estimate of -$1.02 and a low estimate of -$1.58, while EPS last year was -$1.17. The consensus estimate for the next quarter is -$1.29, with high estimates of -$0.98 and low estimates of -$1.68.
Analysts are recommending an EPS of between -$4.55 and -$7.07 for the fiscal current year, implying an average EPS of -$5.61. EPS for the following year is -$5.49, with 25.0 analysts recommending between -$1.72 and -$7.59.
Revenue Estimates
For the next quarter, 16 analysts are estimating revenue of $20.29M. There is a high estimate of $44M for the next quarter, whereas the lowest estimate is $3M.
A total of 26 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $102.5M, while the lowest revenue estimate was $9M, resulting in an average revenue estimate of $50.72M. In the same quarter a year ago, actual revenue was $36.27M
